| Literature DB >> 34611415 |
Shufang Lin1, Shuzhen Wei1, Yong Zhao1, Zhisong Dai1, Jian Lin1, Yu Pang2.
Abstract
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) isolates collected from Fujian province, China were assessed for molecular epidemiological characteristics. Analysis of isolate genotype profiles revealed that the Beijing genotype was associated with especially high drug resistance and community transmission rates.Entities:
Keywords: Mycobacterium tuberculosis; genotype; multidrug resistance; pncA; pyrazinamide
Year: 2021 PMID: 34611415 PMCID: PMC8487280 DOI: 10.2147/IDR.S331516
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Spoligotypes Shared by MDR-TB Clinical Isolates Evaluated in This Study
| SITa | Lineage/Sublineageb | Spoligotypes in Binary | Octal | Noc.(%) |
|---|---|---|---|---|
| 1 | Beijing | □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ | 000000000003771 | 75 |
| 250 | Beijing | □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■ | 000000000000371 | 3 |
| 190 | Beijing-like | □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■□■■■ | 000000000003731 | 1 |
| 585 | Beijing-like | □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■ | 000000000000031 | 1 |
| 36 | H3-T3 | ■■■■■■■■■■■■□■■■■■■■■■■■■■■■■■□■□□□□■■■■■■■ | 777,737,777,720,771 | 3 |
| 50 | H3 | ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■□□□□■■■■■■■ | 777,777,777,720,771 | 7 |
| 467 | H3 | □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■□□□□■■■■■■■ | 000000000020771 | 2 |
| 742 | H | ■■■■■■■■■■■■■■■■■■■■■■■■□□□□□□□■□□□□■■■■■■■ | 777,777,770,020,771 | 1 |
| 946 | H | ■■■■■■■■■■■■■■■■■■■■■■□□□□□□□□□■□□□□■■■■■■■ | 777,777,740,020,771 | 1 |
| 53 | T1 | ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ | 777,777,777,760,771 | 7 |
| 334 | T1 | ■□■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ | 577,777,777,760,771 | 1 |
| 1098 | T2 | ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□□■■□■■■ | 777,777,777,760,331 | 1 |
| 254 | T5-RUS1 | ■■■■■■■■■■■■■■□□□□□□□□□□■■■■■■■■□□□□■■■■■■■ | 777,760,007,760,771 | 1 |
| 1163 | T3 | ■■□■■■■■■■■■□■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ | 677,737,777,760,771 | 1 |
| 37 | T3 | ■■■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ | 777,737,777,760,771 | 3 |
| 1462 | U | ■■■■■■■■■■■■■■■■■■■■■■■■□□□□□□□□□□■■■■■■■■■ | 777,777,770,003,771 | 1 |
| 246 | U | ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■ | 777,777,777,777,731 | 1 |
| 1634 | MANU2 | ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■□□■■■■■■■■■ | 777,777,777,723,771 | 1 |
| Undesignated | ■■■■■□□□□■□■■■■■■■■■■■■■■■■■■■■■□□□□■■■□■■■ | 760,577,777,760,731 | 1 | |
| Undesignated | ■■■■■■■□□□□□□□□□□□□■■■■■■■■■■■□■□□□□■■■■■■■ | 774,000,377,720,771 | 1 | |
| Undesignated | ■■■■■■■■■■■■■■■■■■■■■■■■■□□■■■■■□□□□■■■□■■■ | 777,777,774,760,731 | 1 | |
| Undesignated | ■■■■■■■■■■■■■□□□□□□■■■■■■■■■■■□■□□□□■■■□□■■ | 777,740,377,720,711 | 1 | |
| Undesignated | ■■■■■■■■■■■■■■■■■■■■■■■■□□□□□□□□□□□□□□□□■■■ | 777,777,770,000,031 | 1 | |
| Undesignated | ■■■■■■■■■■■■■■■■■■■■■□□■■□□■□□□□■□■■□□■■■□□ | 777,777,714,413,160 | 1 | |
| Undesignated | ■■■■■■■■■■■■■■■■■■■□■■■■■■■■■■■■■■□□■■■■■■■ | 777,777,577,774,771 | 1 | |
| Undesignated | ■■■■■■■■■□□□□■■■■■■■■■■■■■■■■■□■□□□□■■■■■■■ | 777,037,777,720,771 | 1 |
Notes: aSIT from SpolDB4.0, bRepresenting spoligotypes families as assigned in the SpolDB4.0 database, CNumber of strains with an identical SIT. □It means there is no hybrid signal; ■It means there is a hybrid signal.
The Drug Resistant Rates of Different Families Compared in This Study
| Resistant | Beijing (N=80,%) | Non-Beijing (N=39,%) | Total (N=119, %) | P value |
|---|---|---|---|---|
| EMB | 49(61.3) | 25(64.1) | 74(62.2) | 0.763 |
| SM | 49(61.3) | 20(51.3) | 69(58.0) | 0.301 |
| PZA | 31(38.8) | 13(33.3) | 44(37.0) | 0.566 |
| OFLX | 24(30.0) | 8(20.5) | 32(26.9) | 0.273 |
| KM | 9(11.3) | 4(10.3) | 13(10.9) | 0.870 |
Abbreviations: EMB, ethambutol; SM, streptomycin; PZA, pyrazinamide; OFLX, ofloxacin; KM, kanamycin; N, numbers of the strains.
Characteristics in MDR-TB Strains Between the Beijing and Non-Beijing Family
| Characteristics | Spoligotypes | OR (95% CI) | |||
|---|---|---|---|---|---|
| Beijing (N=80, %) | Non-Beijing (N=39, %) | Total (N=119,%) | |||
| Gender | |||||
| Male | 60(75.0) | 31(79.5) | 91(76.5) | 0.59 | 0.77(0.31–1.96) |
| Female | 20(25.0) | 8(20.5) | 28(23.5) | – | 1.0(Ref.) |
| Age group, years | |||||
| 0–24 | 9(11.3) | 0(0) | 9(7.6) | – | 1.0(Ref.) |
| 25–44 | 28(35.0) | 17(43.6) | 45(37.8) | 0.03 | 1.61(1.28–2.02) |
| ≥45 | 43(53.8) | 22(56.4) | 65(54.6) | 0.04 | 1.51(1.27–1.80) |
| Farmer | |||||
| Yes | 43(53.8) | 23(59.0) | 66(55.5) | – | 1.0(Ref.) |
| No | 37(46.3) | 16(41.0) | 53(44.5) | 0.59 | 0.81(0.37–1.75) |
| Education | |||||
| Illiterate | 16(20.0) | 9(23.1) | 25(21.0) | – | 1.0(Ref.) |
| Literate | 64(80.0) | 30(76.9) | 94(79.0) | 0.70 | 0.83(0.33–2.10) |
| Areas | |||||
| Coastal areas | 61(76.3) | 35(89.8) | 80(67.2) | – | 1.0(Ref.) |
| Mainland areas | 19(23.8) | 4(10.3) | 39(32.8) | 0.08 | 0.37(0.12–1.67) |
| Treatment history | |||||
| New case | 41(51.3) | 18(46.2) | 59(49.6) | – | 1.0(Ref.) |
| Retreated | 39(48.8) | 21(53.9) | 60(50.4) | 0.60 | 1.23(0.57–2.64) |
Abbreviation: N, numbers of the strains.
Figure 1MDR-TB isolates genotyped by 24 loci MIRU-VNTR.
HGDI of 24-Loci VNTR for MDR-TB Strains
| 24-Loci VNTR | HGDI (All Strains) | HGDI (Beijing) | HGDI (Non-Beijing) | Size Range Observed | No. of Alleles Observed | 15-LociVNTR | Diversity* |
|---|---|---|---|---|---|---|---|
| QUB11B | 0.7958 | 0.7282 | 0.8151 | 1–7 | 7 | √ | High |
| QUB26 | 0.7260 | 0.6788 | 0.7989 | 1–9 | 8 | √ | High |
| MTUB21 | 0.7125 | 0.5794 | 0.6734 | 1–6 | 6 | √ | High |
| ETRE | 0.6627 | 0.4756 | 0.6005 | 2–5 | 4 | √ | High |
| MIRU23 | 0.5538 | 0.5377 | 0.6221 | 1–4 | 4 | Moderate | |
| MTUB04 | 0.5275 | 0.2731 | 0.5223 | 1–4 | 6 | √ | Moderate |
| MIRU26 | 0.5177 | 0.2684 | 0.5547 | 2–6 | 5 | √ | Moderate |
| MIRU10 | 0.5044 | 0.3209 | 0.5533 | 1–5 | 5 | √ | Moderate |
| QUB4156C | 0.5031 | 0.5294 | 0.4561 | 1–4 | 4 | √ | Moderate |
| MIRU39 | 0.4883 | 0.3364 | 0.5776 | 2–4 | 4 | √ | Moderate |
| MIRU27 | 0.4737 | 0.3861 | 0.6262 | 1–4 | 4 | Moderate | |
| ETRA | 0.4519 | 0.1861 | 0.3645 | 2–8 | 5 | √ | Moderate |
| MIRU16 | 0.4243 | 0.3820 | 0.5304 | 1–4 | 4 | √ | Moderate |
| MTUB30 | 0.4078 | 0.0497 | 0.3023 | 2–4 | 3 | √ | Moderate |
| MIRU40 | 0.4014 | 0.3285 | 0.5304 | 1–4 | 4 | √ | Moderate |
| ETRB | 0.3896 | 0.1415 | 0.5452 | 1–3 | 3 | Moderate | |
| MTUB29 | 0.3493 | 0.2902 | 0.4845 | 2–5 | 4 | Moderate | |
| MTUB39 | 0.3197 | 0.2544 | 0.4602 | 1–6 | 6 | Moderate | |
| ETRC | 0.2657 | 0.2326 | 0.3563 | 1–5 | 5 | √ | Poor |
| ETRD | 0.2238 | 0.1617 | 0.3644 | 1–6 | 6 | √ | Poor |
| MTUB34 | 0.0736 | 0.0494 | 0.1457 | 2–4 | 3 | Poor | |
| MIRU24 | 0.0083 | 0 | 0.0513 | 1–2 | 2 | Poor | |
| MIRU02 | 0 | 0 | 0 | 1 | 1 | Poor | |
| MIRU20 | 0 | 0 | 0 | 1 | 1 | Poor |
Notes: HGDI represents the value of allelic diversity of each locus. *The VNTR loci were designated as high, moderate, and poor discriminatory at h of >0.6, ⩾0.3 and ⩽0.6, and <0.3, respectively.
Characteristics in MDR-TB Strains Between the Clustered and Individual Strain Family
| Characteristics | Strains | Total (N=119,%) | OR (95% CI) | ||
|---|---|---|---|---|---|
| Clustered (N=14,%) | Non-Clustered (N=105,%) | ||||
| Gender | |||||
| Male | 11(78.6) | 80(76.2) | 91(76.5) | 0.84 | 0.87(0.23–3.38) |
| Female | 3(21.4) | 25(23.8) | 28(23.5) | – | 1.0(Ref.) |
| Age group, years | |||||
| 0–24 | 1(7.1) | 8(7.6) | 9(7.6) | – | 1.0(Ref.) |
| 25–44 | 4(28.6) | 41(39.1) | 45(37.8) | 0.84 | 1.28(0.13–13.02) |
| ≥45 | 9(64.3) | 56(53.3) | 65(54.6) | 0.82 | 0.78(0.09–6.98) |
| Family | |||||
| Beijing | 12(85.7) | 68(64.8) | 80(67.2) | 0.12 | 0.31(0.07–1.44) |
| NonBeijing | 2(14.3) | 37(35.2) | 39(32.8) | – | 1.0(Ref.) |
| Treatment history | |||||
| New case | 9(64.3) | 50(47.6) | 59(49.6) | 0.24 | 0.51(0.16–1.61) |
| Retreated | 5(35.7) | 55(52.4) | 60(50.4) | – | 1.0(Ref.) |
| PZA | |||||
| Susceptible | 5(35.7) | 70(66.7) | 75(63.0) | 0.02 | 3.6(1.12–11.56) |
| Resistant | 9(64.3) | 35(33.3) | 44(37.0) | – | 1.0(Ref.) |
| SM | |||||
| Susceptible | 6(42.9) | 44((41.9) | 50(42.0) | 0.95 | 0.96(0.31–2.97) |
| Resistant | 8(57.1) | 61(58.1) | 69(57.9) | – | 1.0(Ref.) |
| EMB | |||||
| Susceptible | 4(28.6) | 40(38.1) | 44(37.0) | 0.49 | 1.54(0.45–5.24) |
| Resistant | 10(71.4) | 65(61.9) | 75(63.0) | – | 1.0(Ref.) |
| OFLX | |||||
| Susceptible | 7(50.0) | 80(76.2) | 97(81.5) | 0.04 | 3.2(1.02–10.00) |
| Resistant | 7(50.0) | 25(23.8) | 32(26.9) | ||
| KM | |||||
| Susceptible | 13(92.9) | 93(88.6) | 106(89.1) | 0.63 | 0.6(0.07–4.97) |
| Resistant | 1(7.1) | 12(11.4) | 13(10.9) | ||
Abbreviations: PZA, pyrazinamide; SM, streptomycin; EMB, ethambutol; OFLX, ofloxacin; KM, kanamycin; N, numbers of the strains.
The Mutations in pncA Detected in the PZA Resistance MDR Strains
| PZA Susceptibility | Codon | Amino Acid Change | ||
|---|---|---|---|---|
| S | R | |||
| 0 | 2 | 22G→A | GAC8AAC | D8N |
| 0 | 1 | 29A→C | CAG10CCG | Q10P |
| 0 | 1 | 42C→A | TGC14TGA | C14end |
| 0 | 1 | 137C→A | GCA46GAA | A46E |
| 0 | 1 | 137C→T | GCA46GTA | A46V |
| 0 | 1 | 152A→C | CAC51CCC | H51P |
| 0 | 3 | 202T→C | TGG68CGG | W68R |
| 0 | 1 | 231Ins | 231Insert | Frameshift |
| 0 | 1 | 246A→C | CAT82CCT | H82P |
| 0 | 4 | 311G→T | AGC104ATC | S104I |
| 0 | 1 | 347T→C | CTG116CCG | L116P |
| 0 | 2 | 389Ins | 389Insert | Frameshift |
| 0 | 1 | 403A→C | ACC135CCC | T135P |
| 0 | 2 | 421C→T | CAG141TAG | Q141end |
| 0 | 1 | 422A→C | CAG141CCG | Q141P |
| 0 | 1 | 478A→G | ACA160GCA | T160A |
| 0 | 1 | 490T→C | TCG164CCG | S164P |
| 0 | 1 | 523A→G | ATG175GTG | M175V |
| 0 | 1 | 278T→G, 319G→A, 376G→A, 422A→C, 541G→A | TCG93TCA, GAG112AAG, CAG141CCG, GAT126AAT, GAG181AAG | V93G, E112K, Q141P, D126N, E181K |
| 1 | 0 | 136G→A | GCA46ACA | A46T |
| 2 | 0 | 345A→C | CCA115CCC | Synonymous mutation |
| 1 | 0 | 383T→G | GTC128GGC | V128G |
| 1 | 0 | 396T→C | GGT132GGC | Synonymous mutation |
| 1 | 0 | 398T→C | ATT133ACT | I133T |
| 1 | 1 | 464T→G | GTG155GGG | V155G |
Abbreviations: PZA, pyrazinamide; S, susceptible; R, resistance.